Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519446088> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W1519446088 abstract "The deployment of cancer therapeutics that exploit oncogenic dependencies has yielded remarkable advances in patient treatment. However, the therapeutic benefit of these approaches is transient and the majority of patients develop resistance within several months. BRAF V600E -mutant malignant melanoma provides an illustrative example of this phenomenon: treatment with RAF and MEK inhibitors yields clinical responses in 50-80% of patients. However, 10-20% fail to respond to treatment (intrinsic resistance) and patients that do respond become drug resistant within ∼9 months (acquired resistance), presenting a formidable and unsolved clinical challenge. It remains incompletely understood why a subset of BRAF V600 -mutant melanoma patients (10-20%) fail to respond to MAPK-pathway inhibition. Here, we show that RAF inhibitor sensitive and resistant BRAF V600 -mutant melanomas display distinct transcriptional profiles. RAF-inhibitor sensitive cell lines are distinguishable by expression and activity of the melanocytic lineage transcription factor MITF, whereas intrinsically drug-resistant cell lines are defined by expression of the receptor tyrosine kinase AXL and elevated levels of NF-κB signaling. In vitro, these signatures were sufficient to predict MAPK-pathway inhibitor responsiveness in independent panels of melanoma cell lines. MITF-low, AXL/NF-κB high melanomas were resistant to single-agent RAF, MEK and ERK and combined RAF/MEK inhibition. In treatment-naive patient biopsies, markers of the drug sensitive transcriptional states were associated with improved therapeutic responses to combined RAF/MEK inhibitors in BRAF V600 -mutant melanoma. Moreover, in cell lines, NF-κB activation antagonized MITF expression and induced both resistance marker genes and drug resistance. Thus, distinct cell states characterized by MITF and AXL/NF-κB activity can influence intrinsic resistance to MAPK pathway inhibitors in BRAF V600 -mutant melanoma. More broadly, these data suggest that the transcriptional context in which an oncogenic event arises can have a profound impact on the establishment of oncogene-dependencies and associated drug susceptibilities. Citation Format: Cory Johannessen, David Konieczkowski, Omar Abudayyeh, Jong Wook Kim, Zachary Cooper, Adriano Piris, Dennie Frederick, Michal Barzily-Rokni, Ravid Straussman, Rizwan Haq, David Fisher, Jill Mesirov, William Hahn, Keith Flaherty, Jennifer Wargo, Pablo Tamayo, Levi Garraway. A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr PR04." @default.
- W1519446088 created "2016-06-24" @default.
- W1519446088 creator A5014864191 @default.
- W1519446088 creator A5017114712 @default.
- W1519446088 creator A5022484206 @default.
- W1519446088 creator A5023174631 @default.
- W1519446088 creator A5024022789 @default.
- W1519446088 creator A5024756972 @default.
- W1519446088 creator A5025259421 @default.
- W1519446088 creator A5035427219 @default.
- W1519446088 creator A5039291634 @default.
- W1519446088 creator A5047185974 @default.
- W1519446088 creator A5055048393 @default.
- W1519446088 creator A5061984381 @default.
- W1519446088 creator A5063875415 @default.
- W1519446088 creator A5071770314 @default.
- W1519446088 creator A5077622597 @default.
- W1519446088 creator A5078874539 @default.
- W1519446088 creator A5091053901 @default.
- W1519446088 date "2015-02-13" @default.
- W1519446088 modified "2023-09-22" @default.
- W1519446088 title "Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors" @default.
- W1519446088 doi "https://doi.org/10.1158/1557-3265.pms14-pr04" @default.
- W1519446088 hasPublicationYear "2015" @default.
- W1519446088 type Work @default.
- W1519446088 sameAs 1519446088 @default.
- W1519446088 citedByCount "1" @default.
- W1519446088 countsByYear W15194460882015 @default.
- W1519446088 crossrefType "proceedings-article" @default.
- W1519446088 hasAuthorship W1519446088A5014864191 @default.
- W1519446088 hasAuthorship W1519446088A5017114712 @default.
- W1519446088 hasAuthorship W1519446088A5022484206 @default.
- W1519446088 hasAuthorship W1519446088A5023174631 @default.
- W1519446088 hasAuthorship W1519446088A5024022789 @default.
- W1519446088 hasAuthorship W1519446088A5024756972 @default.
- W1519446088 hasAuthorship W1519446088A5025259421 @default.
- W1519446088 hasAuthorship W1519446088A5035427219 @default.
- W1519446088 hasAuthorship W1519446088A5039291634 @default.
- W1519446088 hasAuthorship W1519446088A5047185974 @default.
- W1519446088 hasAuthorship W1519446088A5055048393 @default.
- W1519446088 hasAuthorship W1519446088A5061984381 @default.
- W1519446088 hasAuthorship W1519446088A5063875415 @default.
- W1519446088 hasAuthorship W1519446088A5071770314 @default.
- W1519446088 hasAuthorship W1519446088A5077622597 @default.
- W1519446088 hasAuthorship W1519446088A5078874539 @default.
- W1519446088 hasAuthorship W1519446088A5091053901 @default.
- W1519446088 hasConcept C104317684 @default.
- W1519446088 hasConcept C121608353 @default.
- W1519446088 hasConcept C177504595 @default.
- W1519446088 hasConcept C184235292 @default.
- W1519446088 hasConcept C2777658100 @default.
- W1519446088 hasConcept C2781249067 @default.
- W1519446088 hasConcept C502942594 @default.
- W1519446088 hasConcept C54355233 @default.
- W1519446088 hasConcept C57074206 @default.
- W1519446088 hasConcept C71924100 @default.
- W1519446088 hasConcept C86339819 @default.
- W1519446088 hasConcept C86803240 @default.
- W1519446088 hasConceptScore W1519446088C104317684 @default.
- W1519446088 hasConceptScore W1519446088C121608353 @default.
- W1519446088 hasConceptScore W1519446088C177504595 @default.
- W1519446088 hasConceptScore W1519446088C184235292 @default.
- W1519446088 hasConceptScore W1519446088C2777658100 @default.
- W1519446088 hasConceptScore W1519446088C2781249067 @default.
- W1519446088 hasConceptScore W1519446088C502942594 @default.
- W1519446088 hasConceptScore W1519446088C54355233 @default.
- W1519446088 hasConceptScore W1519446088C57074206 @default.
- W1519446088 hasConceptScore W1519446088C71924100 @default.
- W1519446088 hasConceptScore W1519446088C86339819 @default.
- W1519446088 hasConceptScore W1519446088C86803240 @default.
- W1519446088 hasLocation W15194460881 @default.
- W1519446088 hasOpenAccess W1519446088 @default.
- W1519446088 hasPrimaryLocation W15194460881 @default.
- W1519446088 hasRelatedWork W1731462893 @default.
- W1519446088 hasRelatedWork W1825058545 @default.
- W1519446088 hasRelatedWork W1984623460 @default.
- W1519446088 hasRelatedWork W2032211985 @default.
- W1519446088 hasRelatedWork W2033014187 @default.
- W1519446088 hasRelatedWork W2038655858 @default.
- W1519446088 hasRelatedWork W2042950481 @default.
- W1519446088 hasRelatedWork W2062758319 @default.
- W1519446088 hasRelatedWork W2080626878 @default.
- W1519446088 hasRelatedWork W2081295565 @default.
- W1519446088 hasRelatedWork W2107890733 @default.
- W1519446088 hasRelatedWork W2158089046 @default.
- W1519446088 hasRelatedWork W2168420784 @default.
- W1519446088 hasRelatedWork W2314505282 @default.
- W1519446088 hasRelatedWork W2740295931 @default.
- W1519446088 hasRelatedWork W2757812714 @default.
- W1519446088 hasRelatedWork W2793780677 @default.
- W1519446088 hasRelatedWork W2887615275 @default.
- W1519446088 hasRelatedWork W2913242533 @default.
- W1519446088 hasRelatedWork W2922370156 @default.
- W1519446088 isParatext "false" @default.
- W1519446088 isRetracted "false" @default.
- W1519446088 magId "1519446088" @default.
- W1519446088 workType "article" @default.